Divi's Laboratories (NSE:DIVISLAB) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
94 GF Score
Price ₹6,938.50
GF Value ₹6,780.56
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Divi's Laboratories Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

NSE:DIVISLAB
94GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹6,938.50 is trading 2.3% above its estimated GF Value™ of ₹6,780.56. GuruFocus considers Divi's Laboratories to be Fairly Valued.

Key valuation signals for NSE:DIVISLAB:

  • Cash Payments:
  • GF Value™: ₹6,780.56 vs. price of ₹6,938.50 (2.3% above fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
94GF Score

Get the complete analysis for NSE:DIVISLAB

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,938.50
Price
₹6,780.56
GF Value